PFS
Figure 3. · Panel Angiogenesis_-_Low
Panel Angiogenesis_-_Low 是同一 Figure 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
R J Motzer, C Porta, M Eto, T E Hutson, S Y Rha, J R Merchan, E Winquist, H Gurney, V Grünwald, S George, J Markensohn, J E Burgents, R Cristescu, P Sachdev, Y Narita, J Huang, Z Zhao, C E Okpara, Y Minoshima, T K Choueiri
Ann Oncol 36(4) 375-386
BACKGROUND: In CLEAR, lenvatinib + pembrolizumab (L + P) significantly improved efficacy versus sunitinib in first-line treatment of patients with advanced renal cell carcinoma (aRCC). We report results from CLEAR biomarker analyses. PATIENTS AND METHODS: Programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) and next-generation sequencing assays (whole exome sequencing/RNA sequencing) were carried out on archival tumor specimens. For IHC-derived/RNA sequencing analyses, a continuous analysis was carried out adjusting by Karnofsky performance status (KPS) score for: PD-L1 combined positive score (CPS) versus best overall response (BOR)/progression-free survival (PFS); and each gene signature score [T-cell inflamed gene expression profile (TcellinfGEP)/non-TcellinfGEP signatures including proliferation and angiogenesis] versus BOR/PFS. Association between mutation status of RCC driver genes and PFS were analyzed for genes for which ≥20 patients per arm had oncogenic alterations. Association of molecular subtypes with outcome was evaluated with baseline KPS adjustments. The set of biomarkers evaluated and statistical significance criteria for PD-L1 CPS, gene signature scores, and molecular subtypes were prespecified. RESULTS: Within-arm analyses using continuous values showed no association between PD-L1 levels and BOR/PFS for either treatment. PFS hazard ratios between arms were similar regardless of the mutant or wild-type subgroups of RCC driver genes (VHL, PBRM1, SETD2, BAP1, KDM5C). No associations between PFS and gene signature scores were observed for L + P. With sunitinib, high proliferation and MYC signature scores showed shorter PFS; high angiogenesis and microvessel density signature scores showed longer PFS. Six new molecular subtypes were defined. Tumors of patients with favorable/intermediate risk were enriched in angiogenesis and angiogenesis/stromal clusters; those with poor risk were enriched in proliferative and unclassified (low-TcellinfGEP/low-angiogenesis/low-proliferation) clusters. No association between molecular subtypes and PFS for L + P/sunitinib was observed (after adjustment for KPS and gene signatures that were individually associated with PFS). CONCLUSIONS: Improvements in objective response rate and PFS for L + P versus sunitinib in aRCC were observed consistently across a range of biomarker subgroups defined using RCC driver mutations, PD-L1, gene expression signatures, and molecular subtypes.
1 个 Figure · 10 个 KM 面板
Analyses of gene signature scores. A) Within-arm association analysis of continuous gene signature scores by BOR, and B) between-arm association analysis of gene signature scores by PFS for signature-high and -low subgroups separately; C) Kaplan-Meier curves of PFS between arms for signature-high and -low subgroups separately. Cutoff values (1st tertile of Tcell inf GEP, median of non-Tcell inf GEP signatures) were determined based on the combined three arms. High/non-low: >= cutoff; low: <cutoff. For figure 3A , P -values in the boxplots were for within-arm testing and were calculated using logistic regression adjusted by KPS, one-sided and nominal for Tcell inf GEP in the L+P arm, two-sided and nominal for Tcell inf GEP in the S arm, and two-sided and BH FDR adjusted for non-Tcell inf GEP signatures. Angio36, angiogenic & growth factor pathway; BOR, best overall response; BH, Benjamini Hochberg; CI, confidence interval; EMT, epithelial-mesenchymal transition; FDR, false discovery rate; HR, hazard ratio; KPS, Karnofsky performance status; L+P, lenvatinib plus pembrolizumab; m/gMDSC, monocytic/granulocytic myeloid-derived suppressor cells; MVD, microvessel density; PFS, progression-free survival; S, sunitinib; Tcell inf GEP, T-cell inflamed gene expression profile.
Figure 3. · Panel Angiogenesis_-_Low
Panel Angiogenesis_-_Low 是同一 Figure 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3. · Panel MVD_-_Low
Panel MVD_-_Low 是同一 Figure 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3. · Panel Proliferation_-_Low
Panel Proliferation_-_Low 是同一 Figure 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3. · Panel MYC_-_Low
Panel MYC_-_Low 是同一 Figure 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3. · Panel GEP_-_Low
Panel GEP_-_Low 是同一 Figure 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3. · Panel Angiogenesis_-_High
Panel Angiogenesis_-_High 是同一 Figure 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3. · Panel MVD_-_High
Panel MVD_-_High 是同一 Figure 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3. · Panel Proliferation_-_High
Panel Proliferation_-_High 是同一 Figure 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3. · Panel MYC_-_High
Panel MYC_-_High 是同一 Figure 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3. · Panel GEP_-_High
Panel GEP_-_High 是同一 Figure 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。